Bifeprunox - Atypical Antipsychotic Drug
Key Data:
Drug (Brand / Generic)
Bifeprunox mesilate
Company / Licensee
Solvay Pharmaceuticals / Lundbeck / Wyeth
Therapy Class
Antipsychotic
Product Description
Partial dopamine D2 agonist
Current Indication
Treatment of schizophrenia
Market Sector
CNS
Development Status
Phase III Europe; rejected by FDA in US
